1
|
Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC, Hieble JP, McCafferty G, Ward KW, Adams JL, Bondinell WE, Underwood DC, Osborn RR, Badger AM, Sarau HM. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 2001; 166:6341-8. [PMID: 11342658 DOI: 10.4049/jimmunol.166.10.6341] [Citation(s) in RCA: 148] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The anaphylatoxin C3a is a potent chemotactic peptide and inflammatory mediator released during complement activation which binds to and activates a G-protein-coupled receptor. Molecular cloning of the C3aR has facilitated studies to identify nonpeptide antagonists of the C3aR. A chemical lead that selectively inhibited the C3aR in a high throughput screen was identified and chemically optimized. The resulting antagonist, N(2)-[(2,2-diphenylethoxy)acetyl]-L-arginine (SB 290157), functioned as a competitive antagonist of (125)I-C3a radioligand binding to rat basophilic leukemia (RBL)-2H3 cells expressing the human C3aR (RBL-C3aR), with an IC(50) of 200 nM. SB 290157 was a functional antagonist, blocking C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca(2+) mobilization in RBL-C3aR cells and human neutrophils with IC(50)s of 27.7 and 28 nM, respectively. SB 290157 was selective for the C3aR in that it did not antagonize the C5aR or six other chemotactic G protein-coupled receptors. Functional antagonism was not solely limited to the human C3aR; SB 290157 also inhibited C3a-induced Ca(2+) mobilization of RBL-2H3 cells expressing the mouse and guinea pig C3aRS: It potently inhibited C3a-mediated ATP release from guinea pig platelets and inhibited C3a-induced potentiation of the contractile response to field stimulation of perfused rat caudal artery. Furthermore, in animal models, SB 290157, inhibited neutrophil recruitment in a guinea pig LPS-induced airway neutrophilia model and decreased paw edema in a rat adjuvant-induced arthritis model. This selective antagonist may be useful to define the physiological and pathophysiological roles of the C3aR.
Collapse
MESH Headings
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/metabolism
- Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics
- Anti-Inflammatory Agents, Non-Steroidal/pharmacology
- Arginine/analogs & derivatives
- Arginine/metabolism
- Arginine/pharmacokinetics
- Arginine/pharmacology
- Arthritis, Experimental/immunology
- Arthritis, Experimental/pathology
- Benzhydryl Compounds/metabolism
- Benzhydryl Compounds/pharmacokinetics
- Benzhydryl Compounds/pharmacology
- Binding, Competitive
- Cell Line
- Complement C3a/metabolism
- Complement Inactivator Proteins/metabolism
- Complement Inactivator Proteins/pharmacokinetics
- Complement Inactivator Proteins/pharmacology
- Disease Models, Animal
- Edema/pathology
- Edema/prevention & control
- Guinea Pigs
- Hindlimb
- Humans
- Injections, Intraperitoneal
- Leukocytosis/immunology
- Leukocytosis/pathology
- Male
- Membrane Proteins
- Mice
- Muscle Contraction/drug effects
- Neutrophil Infiltration/drug effects
- Rats
- Rats, Inbred Lew
- Rats, Sprague-Dawley
- Receptors, Complement/antagonists & inhibitors
- Receptors, Complement/metabolism
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- R S Ames
- Department of Molecular Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000; 43:22-6. [PMID: 10633035 DOI: 10.1021/jm990446u] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- W H Miller
- Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, Mumaw JA, Newlander KA, Pirhalla JL, Roethke TJ, Salyers KL, Souder PR, Stelman GJ, Smith BR. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 1999; 27:1232-41. [PMID: 10534306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
Allometric scaling may be used in drug development to predict the pharmacokinetics of xenobiotics in humans from animal data. Although allometry may be successful for compounds that are excreted unchanged or that are oxidatively metabolized (with corrections for metabolic capacity), it has been more challenging for compounds excreted primarily as conjugates in bile. (S)-10, 11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[ a, d]cycloheptene-10-acetic acid (SB-265123) is a novel alphavbeta3 ("vitronectin receptor") antagonist. In this study, the in vivo pharmacokinetics and in vitro plasma protein binding of SB-265123 were examined in four species: mice, rats, dogs, and monkeys. In monkeys and dogs, SB-265123 exhibited moderate clearance, whereas low clearance (<20% hepatic blood flow) was observed in the rat, and high clearance (>70% hepatic blood flow) was seen in the mouse. The concentration-time profiles indicated the possibility of enterohepatic recirculation; subsequent studies in bile duct-cannulated rats demonstrated extensive biliary excretion of an acyl-glucuronide of SB-265123. In allometric scaling to predict the disposition of SB-265123 in humans, various standard correction factors were applied, including protein binding, maximum lifespan potential, and brain weight; each failed to produce adequate interspecies scaling of clearance (r(2) < 0.72). Consequently, a novel correction factor incorporating bile flow and microsomal UDP-glucuronosyltransferase activity in each species was applied, demonstrating substantial improvement in the correlation of the allometric plot (r(2) = 0.96). This study demonstrates a novel allometric correction that may be applicable to compounds that undergo conjugation and biliary excretion.
Collapse
Affiliation(s)
- K W Ward
- Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals R&D, King of Prussia, Pennsylvania 19406, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 1999; 9:1807-12. [PMID: 10406646 DOI: 10.1016/s0960-894x(99)00283-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.
Collapse
Affiliation(s)
- W H Miller
- Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Keenan RM, Miller WH, Barton LS, Bondinell WE, Cousins RD, Eppley DF, Hwang SM, Kwon C, Lago MA, Nguyen TT, Smith BR, Uzinskas IN, Yuan CC. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. Bioorg Med Chem Lett 1999; 9:1801-6. [PMID: 10406645 DOI: 10.1016/s0960-894x(99)00282-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A peptide RGD analog containing a novel 2-aminopyridine arginine mimetic was discovered to have good affinity and selectivity for the vitronectin receptor. Incorporation of the 2-aminopyridine arginine mimetic into the 3-oxo-1,4-benzodiazepine-2-acetic acid integrin antagonist series led to novel and potent nonpeptide vitronectin receptor antagonists with promising levels of oral bioavailability.
Collapse
Affiliation(s)
- R M Keenan
- Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Keenan RM, Miller WH, Lago MA, Ali FE, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Hwang SM, Jakas DR, Ku TW, Kwon C, Nguyen TT, Reader VA, Rieman DJ, Ross ST, Takata DT, Uzinskas IN, Yuan CC, Smith BR. Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists. Bioorg Med Chem Lett 1998; 8:3165-70. [PMID: 9873696 DOI: 10.1016/s0960-894x(98)00555-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In a 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists containing a benzimidazole as a novel arginine mimetic, we examined the effects of benzimidazole modifications and amide substitutions on both activity and pharmacokinetics.
Collapse
Affiliation(s)
- R M Keenan
- Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Keenan RM, Lago MA, Miller WH, Ali FE, Cousins RD, Hall LB, Hwang SM, Jakas DR, Kwon C, Louden C, Nguyen TT, Ohlstein EH, Rieman DJ, Ross ST, Samanen JM, Smith BR, Stadel J, Takata DT, Vickery L, Yuan CC, Yue TL. Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Bioorg Med Chem Lett 1998; 8:3171-6. [PMID: 9873697 DOI: 10.1016/s0960-894x(98)00556-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model.
Collapse
Affiliation(s)
- R M Keenan
- Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Belz J, Cousins RD, Diwan MV, Eckhause M, Ecklund KM, Hancock AD, Highland VL, Hoff C, Hoffmann GW, Irwin GM, Kane JR, Kettell SH, Klein JR, Kuang Y, Lang K, Martin R, May M, McDonough J, Molzon WR, Riley PJ, Ritchie JL, Schwartz AJ, Trandafir A, Ware B, Welsh RE, White SN, Witkowski MT, Wojcicki SG, Worm S. Search for the weak decay of an H dibaryon. Phys Rev Lett 1996; 76:3277-3280. [PMID: 10060926 DOI: 10.1103/physrevlett.76.3277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
9
|
Belz J, Cousins RD, Diwan MV, Eckhause M, Ecklund KM, Fitch VL, Hancock AD, Highland VL, Hoff C, Hoffmann GW, Irwin GM, Kane JR, Kettell SH, Klein JR, Kuang Y, Lang K, Martin R, May M, McDonough J, Molzon WR, Riley PJ, Ritchie JL, Schwartz AJ, Trandafir A, Ware B, Welsh RE, White SN, Witkowski MT, Wojcicki SG, Worm S. Search for diffractive dissociation of a long-lived H dibaryon. Phys Rev D Part Fields 1996; 53:R3487-R3491. [PMID: 10020412 DOI: 10.1103/physrevd.53.r3487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
10
|
Heinson AP, Horvath J, Knibbe P, Mathiazhagan C, Molzon WR, Urheim J, Arisaka K, Cousins RD, Kaarsberg T, Konigsberg J, Melese P, Rubin P, Slater WE, Wagner D, Hart GW, Kinnison WW, Lee DM, McKee RJ, Milner EC, Sanders GH, Ziock HJ, Axelrod S, Biery KA, Diwan M, Irwin GM, Lang K, Margulies J, Ouimette DA, Schwartz AJ, Wojcicki SG, Auerbach LB, Belz J, Buchholz P, Guss C, Highland VL, Kettell SH, McFarlane WK, Sivertz M, Hoffmann GW, Riley PJ, Ritchie JL, Yamashita A, Chapman MD, Eckhause M, Ginkel JF, Hancock AD, Kane JR, Kenney CJ, Kuang Y, Vulcan WF, Welsh RE, Whyley RJ, Winter RG, Witkowski MT. Measurement of the branching ratio for the rare decay KL0--> micro+ micro-. Phys Rev D Part Fields 1995; 51:985-1013. [PMID: 10018558 DOI: 10.1103/physrevd.51.985] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
11
|
Lee JA, Brinkmann JA, Longton ED, Peishoff CE, Lago MA, Leber JD, Cousins RD, Gao A, Stadel JM, Kumar CS. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry 1994; 33:14543-9. [PMID: 7981216 DOI: 10.1021/bi00252a022] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The potent vasoactive peptide hormone endothelin (ET) binds to receptors which belong to the G-protein coupled receptor family. The availability of non-peptide antagonists for ET receptors allows investigation of the relationship among the binding sites for peptide and non-peptide ligands. In this study, a lysine residue, conserved within transmembrane domain 3 (TM3) of the ETA and ETB receptor subtypes, is implicated in agonist and antagonist binding by its analogous position within TM3 to a binding site aspartate residue conserved within bioactive amine receptors. Replacement of this lysine within hETB by arginine, alanine, methionine, aspartate, or glutamate results in hETB variants with unaltered affinities for agonist peptide ET-1 but which have affinities for peptide agonists ET-2, ET-3, sarafotoxin 6C, and TRL 1736 which are between 1-3 orders of magnitude lower than their corresponding wild-type hETB values. Significantly, the affinities of non-peptide antagonists, (+/-)-SB 209670 and its analogs as well as Ro 46-2005, are abrogated. The results suggest that an interaction of K182 of hETB with the indan 2-carboxyl of (+/-)-SB 209670 may contribute to the high-affinity binding of the diarylindan antagonists. The results indicate that TM3 of hETB is a region of overlap among the binding sites of non-peptide antagonists and the affected peptide agonists.
Collapse
Affiliation(s)
- J A Lee
- Department of Macromolecular Sciences, SmithKline Beechman Pharmaceuticals, King of Prussia, Pennsylvania 19406
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Frazee JS. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A 1994; 91:8052-6. [PMID: 8058755 PMCID: PMC44543 DOI: 10.1073/pnas.91.17.8052] [Citation(s) in RCA: 120] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
An extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist, SB 209670, has been synthesized and characterized. SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki = 0.2 and 18 nM, respectively). SB 209670 produces concentration-dependent inhibition of ET-1-mediated vasoconstriction in isolated vascular tissues and in vivo following either intravenous or intraduodenal administration. SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty. SB 209670 will be useful in characterizing and classifying the physiological and pathophysiological effects of ET.
Collapse
Affiliation(s)
- E H Ohlstein
- Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Elliott JD, Lago MA, Cousins RD, Gao A, Leber JD, Erhard KF, Nambi P, Elshourbagy NA, Kumar C, Lee JA. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J Med Chem 1994; 37:1553-7. [PMID: 8201588 DOI: 10.1021/jm00037a003] [Citation(s) in RCA: 113] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- J D Elliott
- Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Arisaka K, Auerbach LB, Axelrod S, Belz J, Biery KA, Buchholz P, Chapman MD, Cousins RD, Diwan MV, Eckhause M, Ginkel JF, Guss C, Hancock AD, Heinson AP, Highland VL, Hoffmann GW, Horvath J, Irwin GM, Joyce D, Kaarsberg T, Kane JR, Kenney CJ, Kettell SH, Kinnison WW, Knibbe P, Konigsberg J, Kuang Y, Lang K, Lee DM, Margulies J, Mathiazhagan C, McFarlane WK, McKee RJ, Melese P, Milner EC, Molzon WR, Ouimette DA, Riley PJ, Ritchie JL, Rubin P, Sanders GH, Schwartz AJ, Sivertz M, Slater WE, Urheim J, Vulcan WF, Wagner DL, Welsh RE, Whyley RJ, Winter RG, Witkowski MT, Wojcicki SG, Yamashita A, Ziock HJ. Improved sensitivity in a search for the rare decay KL0-->e+e-. Phys Rev Lett 1993; 71:3910-3913. [PMID: 10055106 DOI: 10.1103/physrevlett.71.3910] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
15
|
Arisaka K, Auerbach LB, Axelrod S, Belz J, Biery KA, Buchholz P, Chapman MD, Cousins RD, Diwan MV, Eckhause M, Ginkel JF, Guss C, Hancock AD, Heinson AP, Highland VL, Hoffmann GW, Horvath J, Irwin GM, Joyce D, Kaarsberg T, Kane JR, Kenney CJ, Kettell SH, Kinnison WW, Knibbe P, Konigsberg J, Kuang Y, Lang K, Lee DM, Margulies J, Mathiazhagan C, McFarlane WK, McKee RJ, Melese P, Milner EC, Molzon WR, Ouimette DA, Riley PJ, Ritchie JL, Rubin P, Sanders GH, Schwartz AJ, Sivertz M, Slater WE, Urheim J, Vulcan WF, Wagner DL, Welsh RE, Whyley RJ, Winter RG, Witkowski MT, Wojcicki SG, Yamashita A, Ziock HJ. Improved upper limit on the branching ratio B(KL0--> micro+/-e+/-). Phys Rev Lett 1993; 70:1049-1052. [PMID: 10054273 DOI: 10.1103/physrevlett.70.1049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
16
|
Heinson AP, Horvath J, Mathiazhagan C, Molzon WR, Arisaka K, Cousins RD, Kaarsberg T, Konigsberg J, Rubin P, Slater WE, Wagner DL, Kinnison WW, Lee DM, McKee RJ, Milner EC, Sanders GH, Ziock HJ, Knibbe P, Urheim J, Biery KA, Diwan MV, Irwin GM, Lang K, Margulies J, Ouimette DA, Schwartz A, Wojcicki SG, Auerbach LB, Belz J, Buchholz P, Highland VL, McFarlane WK, Sivertz M, Ritchie JL, Yamashita A, Chapman MD, Eckhause M, Ginkel JF, Hancock AD, Kane JR, Kenney CJ, Kuang Y, Vulcan WF, Welsh RE, Whyley RJ, Winter RG. Higher-statistics measurement of the branching ratio for the decay KL0--> micro micro. Phys Rev D Part Fields 1991; 44:R1-R5. [PMID: 10013746 DOI: 10.1103/physrevd.44.r1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
17
|
Mathiazhagan C, Molzon WR, Cousins RD, Konigsberg J, Kubic J, Melese P, Rubin P, Slater WE, Wagner D, Hart GW, Kinnison WW, Lee DM, McKee RJ, Milner EC, Sanders GH, Ziock HJ, Arisaka K, Knibbe P, Urheim J, Axelrod S, Biery KA, Irwin GM, Lang K, Margulies J, Ouimette DA, Ritchie JL, Trang QH, Wojcicki SG, Auerbach LB, Buchholz P, Highland VL, McFarlane WK, Sivertz M, Chapman MD, Eckhause M, Ginkel JF, Hancock AD, Joyce D, Kane JR, Kenney CJ, Vulcan WF, Welsh RE, Whyley RJ, Winter RG. Measurement of the branching ratio for the decay KL0--> micro micro. Phys Rev Lett 1989; 63:2185-2188. [PMID: 10040822 DOI: 10.1103/physrevlett.63.2185] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
18
|
Mathiazhagan C, Molzon WR, Cousins RD, Konigsberg J, Kubic J, Melese P, Rubin P, Slater WE, Wagner D, Hart GW, Kinnison WW, Lee DM, McKee RJ, Milner EC, Sanders GH, Ziock HJ, Arisaka K, Knibbe P, Urheim J, Axelrod S, Biery KA, Irwin GM, Lang K, Margulies J, Ouimette DA, Ritchie JL, Trang QH, Wojcicki SG, Auerbach LB, Buchholz P, Highland VL, McFarlane WK, Sivertz M, Chapman MD, Eckhause M, Ginkel JF, Hancock AD, Joyce D, Kane JR, Kenney CJ, Vulcan WF, Welsh RE, Whyley RJ, Winter RG. New experimental limits on KL0--> microe and KL0-->ee branching ratios. Phys Rev Lett 1989; 63:2181-2184. [PMID: 10040821 DOI: 10.1103/physrevlett.63.2181] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
19
|
Cousins RD, Konigsberg J, Kubic J, Melese P, Rubin P, Slater WE, Frank JS, Hart GW, Kinnison WW, Lee DM, Milner EC, Sanders GH, Ziock HJ, Arisaka K, Knibbe P, Molzon WR, Urheim J, Wales WD, Axelrod S, Biery KA, Bonneaud G, Irwin GM, Lang K, Martoff CJ, Ouimette DA, Ritchie JL, Trang QH, Wojcicki SG, Auerbach LB, Buchholz P, Highland VL, McFarlane WK, Sivertz MB, Chapman MD, Eckhause M, Ginkel JF, Guss PP, Joyce D, Kane JR, Kenney CJ, Vulcan WF, Welsh RE, Whyley RJ, Winter RG. Search for the decays KL0--> microe and KL0-->ee. Phys Rev D Part Fields 1988; 38:2914-2917. [PMID: 9959470 DOI: 10.1103/physrevd.38.2914] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
20
|
Bernstein RH, Shea TK, Winstein B, Cousins RD, Greenhalgh JF, Schwartz M, Bock GJ, Hedin D, Thomson GB. Search for new, long-lived, neutral particles. Phys Rev D Part Fields 1988; 37:3103-3106. [PMID: 9958593 DOI: 10.1103/physrevd.37.3103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
21
|
Aronson SH, Bernstein RH, Bock GJ, Cousins RD, Greenhalgh JF, Hedin D, Schwartz M, Shea TK, Thomson GB, Winstein B. Measurement of the rate of formation of pi-mu atoms in KL0 decay. Phys Rev D Part Fields 1986; 33:3180-3198. [PMID: 9956535 DOI: 10.1103/physrevd.33.3180] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|